Microbiome Signature Technology

The Biomecite diagnostic technology relies on the analysis of signature genetic sequences obtained directly from patient stool samples. This state-of-the-art technology belongs to the rapidly expanding field of microbiome-based diagnostics, fueled by the development of increasingly efficient and cost-effective DNA-sequencing technologies.

  • Fecal microbiota are attractive and promising diagnostic targets, as they reflect the metabolic, immunologic, and pathologic status of the entire gastrointestinal tract.
  • Sequence analysis of metagenomic DNA isolated from stool samples provides a non-invasive, economical, established and easily automatable way to study the fecal microbiota.
  • To identify diagnostic microbiota markers, the “microbiome signatures”, the inventors developed a statistical, computational method to characterize and compare metagenomic data rapidly and comprehensively.

A PLATFORM TECHNOLOGY

Biomecite Diagnostics is one of the first companies to develop a diagnostic platform based on analysis of DNA data from the human microbiome.

  • A SIMPLE DIAGNOSTIC

    The diagnostic is being developed to provide doctors accurate diagnostic information within days of one simple fecal matter test.

  • AT-HOME TEST

    The test will be available without discomfort or risk to the patient at a low price and could potentially help tens of millions of patients worldwide.

  • SOFTWARE PLATFORM

    The Biomecite diagnostic is a software based platform which will improve over time as more patient data is accumulated.